Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Glucagon-like peptide-1 (GLP-1) receptor agonists

Journal articles and book chapters

23-10-2017 | Insulin | Review | Article

Insulin and its cardiovascular effects: What is the current evidence?

Dongerkery SP, Schroeder PR, Shomali ME. Curr Diab Rep 2017; 17: 120. doi: 10.1007/s11892-017-0955-3

23-10-2017 | Cardiovascular disorders | Review | Article

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

11-10-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

Schnell O et al. Cardiovasc Diabetol 2017; 16: 128. doi: 10.1186/s12933-017-0610-y

05-10-2017 | GLP-1 agonists | Article

Tolerability and effectiveness of exenatide once weekly relative to basal insulin among type 2 diabetes patients of different races in routine care

Nunes AP et al. Diabetes Ther 2017; 8: 1349–1364. doi: 10.1007/s13300-017-0314-z

27-09-2017 | Dyslipidemia | Review | Article

Treatment of dyslipidemia in diabetes: Recent advances and remaining questions

Chait A, Goldberg I. Curr Diab Rep 2017; 17: 112. doi: 10.1007/s11892-017-0942-8

08-09-2017 | Latent autoimmune diabetes of adulthood | Review | Article

Adult-onset autoimmune diabetes: Current knowledge and implications for management

Nat Rev Endocrinol 2017; 13: 674–686. doi: 10.1038/nrendo.2017.99

04-09-2017 | Nephropathy | Review | Article

GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes

Nat Rev Nephrol 2017; 13: 605–628. doi: 10.1038/nrneph.2017.123

23-08-2017 | Obesity | Review | Article

Weight management in patients with type 1 diabetes and obesity

Mottalib A et al. Curr Diab Rep 2017; 17: 92. doi: 10.1007/s11892-017-0918-8

18-08-2017 | Insulin | Review | Article

New basal insulins: A clinical perspective of their use in the treatment of type 2 diabetes and novel treatment options beyond basal insulin

Frias PF, Frias JP. Curr Diab Rep 2017; 17: 91. doi: 10.1007/s11892-017-0926-8

31-07-2017 | Diabetes prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

19-07-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome trial update in diabetes: New evidence, remaining qestions

Herbst R et al. Curr Diab Rep 2017; 17: 67. doi: 10.1007/s11892-017-0898-8

03-07-2017 | Exenatide | Review | Article

A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes

Genovese S, Mannucci E, Ceriello A. Adv Ther 2017; 34: 1791–1814. doi: 10.1007/s12325-017-0499-6

14-05-2017 | Obesity | Review | Article

Medication use for the treatment of diabetes in obese individuals

Wilding JPH. Diabetologia 2017; 61: 265–272. doi: 10.1007/s00125-017-4288-1

16-03-2017 | Glycemic control | Review | Article

Metrics for glycemic control: From HbA1c to continuous glucose monitoring

Nat Rev Endocrinol 2017; 13: 425–436. doi: 10.1038/nrendo.2017.3

16-02-2017 | Type 2 diabetes | In practice | Article

The role of the pharmacist in managing type 2 diabetes with glucagon-like peptide-1 receptor agonists as add-on therapy

Meece J. Adv Ther 2017; 34: 638–657. doi: 10.1007/s12325-017-0491-1

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Xu J, Rajaratnam R. Cardiovasc Diabetol 2017; 16: 18. doi: 10.1186/s12933-017-0499-5

18-01-2017 | Obesity | Review | Article

Medical management of diabesity: Do we have realistic targets?

Pappachan JM, Viswanath AK. Curr Diab Rep 2017; 17: 4. doi: 10.1007/s11892-017-0828-9

15-11-2016 | Heart failure | Review | Article

Novel anti-glycemic drugs and reduction of cardiovascular risk in diabetes: Expectations realized, promises unmet

Flory JH, Ukena JK, Floyd JS. Curr Atheroscler Rep 2016; 18: 79. doi: 10.1007/s11883-016-0633-y

10-11-2016 | Type 2 diabetes | Review | Article

Clinical pharmacokinetics and pharmacodynamics of antihyperglycemic medications in children and adolescents with type 2 diabetes mellitus

Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6

30-09-2016 | SGLT2 inhibitors | Article

Combination therapy with glucagon-like peptide-1 analogues and sodium-glucose cotransporter-2 inhibitors in the management of diabesity: the real world experience

Deol H et al. Endocrine 2017; 55: 173–178. doi: 10.1007/s12020-016-1125-0

Next Previous
Image Credits